Patents by Inventor Fabrizio Gasparini

Fabrizio Gasparini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF MGLUR5 ANTAGONISTS FOR TREATING GAMBLING DISORDER
    Publication number: 20240082215
    Abstract: The present invention relates to the use of mavoglurant in the treatment of gambling disorder. The present invention also relates to the use of mavoglurant in the treatment of gaming disorder.
    Type: Application
    Filed: December 9, 2021
    Publication date: March 14, 2024
    Applicants: Novartis AG, Yale University
    Inventors: Fabrizio GASPARINI, Baltazar GOMEZ-MANCILLA, John KRYSTAL, Vincent MALATERRE, Stephanie O'MALLEY, Godfrey PEARLSON, Marc POTENZA
  • USE OF MGLUR5 ANTAGONISTS FOR TREATING AMPHETAMINE ADDICTION
    Publication number: 20240050408
    Abstract: The invention relates to the mavoglurant, or a pharmaceutically acceptable salt thereof: in the treatment of substance use disorder, wherein the substance is an amphetamine-type stimulant; in a treatment in the reduction of substance use by a substance use disorder patient, wherein the substance is an amphetamine-type stimulant; in a treatment to prevent relapse into substance use by a substance use disorder patient, wherein the substance is an amphetamine-type stimulant; in a treatment to promote substance abstinence by a substance use disorder patient, wherein the substance is an amphetamine-type stimulant; in the treatment of the symptoms of depression or anxiety associated with substance use disorder, wherein the substance is an amphetamine-type stimulant.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 15, 2024
    Applicant: NOVARTIS AG
    Inventors: Fabrizio GASPARINI, Baltazar GOMEZ-MANCILLA,
  • Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
    Patent number: 11878001
    Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of cocaine use by a cocaine use disorder patient; in preventing relapse into cocaine use by a cocaine use disorder patient; in the promotion of cocaine abstinence by a cocaine use disorder patient; in in the treatment of the symptoms of depression or anxiety associated with cocaine use disorder.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: January 23, 2024
    Assignee: NOVARTIS AG
    Inventors: Ricardo Carl Elciario Dolmetsch, Fabrizio Gasparini, Baltazar Gomez-Mancilla, Donald Johns
  • MAVOGLURANT, A MGLUR5 ANTAGONIST, FOR USE IN THE TREATMENT IN THE REDUCTION OF OPIOID USE
    Publication number: 20230270720
    Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of opioid use by an opioid use disorder patient; in preventing relapse into opioid use by an opioid use disorder patient; in the promotion of opioid abstinence by an opioid use disorder patient; in the treatment of the symptoms of depression or anxiety associated with opioid use disorder.
    Type: Application
    Filed: July 15, 2021
    Publication date: August 31, 2023
    Inventors: Richard Carl Elciario DOLMETSCH, Fabrizio GASPARINI, Baltazar GOMEZ-MANCILLA
  • TREM2 STABILIZING ANTIBODIES
    Publication number: 20230167174
    Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.
    Type: Application
    Filed: September 23, 2022
    Publication date: June 1, 2023
    Inventors: Verena BRAND, Dominik FEUERBACH, Fabrizio GASPARINI, Nathalie GEORGE, Eveline SCHAADT, Derya SHIMSHEK, Honnappa SRINIVAS, Markus WALDHUBER, Rainer WILCKEN
  • TREM2 stabilizing antibodies
    Patent number: 11492402
    Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: November 8, 2022
    Assignee: NOVARTIS AG
    Inventors: Verena Brand, Dominik Feuerbach, Fabrizio Gasparini, Nathalie George, Eveline Schaadt, Derya Shimshek, Honnappa Srinivas, Markus Waldhuber, Rainer Wilcken
  • THE USE OF AN MGLUR5 ANTAGONIST FOR TREATING OPIOID ANALGESIC TOLERANCE
    Publication number: 20220175793
    Abstract: The invention relates to the use of a mGluR5 antagonist for the treatment of opioid analgesic tolerance associated with chronic opioid use in chronic pain.
    Type: Application
    Filed: January 28, 2020
    Publication date: June 9, 2022
    Inventors: Richard Carl Elciario DOLMETSCH, Fabrizio GASPARINI, Baltazar GOMEZ-MANCILLA
  • USE OF MAVOGLURANT IN THE REDUCTION OF COCAINE USE OR IN PREVENTING RELAPSE INTO COCAINE USE
    Publication number: 20210093609
    Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of cocaine use by a cocaine use disorder patient; in preventing relapse into cocaine use by a cocaine use disorder patient; in the promotion of cocaine abstinence by a cocaine use disorder patient; in in the treatment of the symptoms of depression or anxiety associated with cocaine use disorder.
    Type: Application
    Filed: July 30, 2018
    Publication date: April 1, 2021
    Inventors: Ricardo Carl Elciario Dolmetsch, Fabrizio Gasparini, Baltazar Gomez-Mancilla, Donald Johns
  • USE OF MAVOGLURANT IN THE REDUCTION OF ALCOHOL USE OR IN PREVENTING RELAPSE INTO ALCOHOL USE
    Publication number: 20200237721
    Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of alcohol use by an alcohol use disorder patient; in preventing relapse into alcohol use by an alcohol use disorder patient; in the promotion of alcohol abstinence by an alcohol use disorder patient; in the treatment of the symptoms of depression or anxiety associated with alcohol use disorder.
    Type: Application
    Filed: July 30, 2018
    Publication date: July 30, 2020
    Inventors: Ricardo Carl Elciario Dolmetsch, Fabrizio Gasparini, Baltazar Gomez-Mancilla, Donald Johns
  • TREM2 STABILIZING ANTIBODIES
    Publication number: 20200140545
    Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.
    Type: Application
    Filed: October 14, 2019
    Publication date: May 7, 2020
    Inventors: Verena BRAND, Dominik FEUERBACH, Fabrizio GASPARINI, Nathalie GEORGE, Eveline SCHAADT, Derya SHIMSHEK, Honnappa SRINIVAS, Markus WALDHUBER, Rainer WILCKEN
  • ORGANIC COMPOUNDS
    Publication number: 20150272929
    Abstract: The invention concerns the use an mGluR modulator, e.g.
    Type: Application
    Filed: June 11, 2015
    Publication date: October 1, 2015
    Inventors: Daniel UMBRICHT, Baltazar Gomez-Mancilla, Fabrizio Gasparini, Therese Di Paolo
  • COMBINATION PRODUCTS
    Publication number: 20140194423
    Abstract: The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor.
    Type: Application
    Filed: March 4, 2014
    Publication date: July 10, 2014
    Inventors: Baltazar Gomez-Mancilla, Fabrizio Gasparini
  • PYRIDYLACETYLENES FOR USE AS RADIOTRACERS AND IMAGING AGENTS
    Publication number: 20140142318
    Abstract: The present invention relates to novel pyridylacetylene derivatives, their preparation, their use as radiotracers/markers and compositions containing them.
    Type: Application
    Filed: January 24, 2014
    Publication date: May 22, 2014
    Applicant: NOVARTIS AG
    Inventors: Fabrizio GASPARINI, Yves AUBERSON, Lea KESSLER, Simon Mensah AMETAMEY
  • Combination products
    Patent number: 8703809
    Abstract: The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: April 22, 2014
    Assignee: Novartis AG
    Inventors: Baltazar Gomez-Mancilla, Fabrizio Gasparini
  • Pyridylacetylenes for use as radiotracers and imaging agents
    Patent number: 8674110
    Abstract: The present invention relates to novel pyridylacetylene derivatives of formula I their preparation, their use as radio-traces/markers and compositions containing them.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: March 18, 2014
    Assignee: Novartis AG
    Inventors: Fabrizio Gasparini, Yves Auberson, Lea Kessler, Simon Mensah Ametamey
  • ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY
    Publication number: 20130331568
    Abstract: The invention provides compounds of formula I wherein n, A, R, R?, R?, R0, X and Y are as defined in the description, and their preparation. The compounds of formula I are useful as pharmaceuticals.
    Type: Application
    Filed: August 15, 2013
    Publication date: December 12, 2013
    Applicant: Novartis AG
    Inventors: Fabrizio Gasparini, Yves Auberson, Silvio Ofner, Terance W. Hart, Kaspar Zimmermann
  • Acetylene derivatives having MGluR 5 antagonistic activity
    Patent number: 8536229
    Abstract: The invention provides compounds of formula I wherein n, A, R, R?, R?, RO, X and Y are as defined in the description, and their preparation. The compounds of formula I are useful as pharmaceuticals.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: September 17, 2013
    Assignee: Novartis AG
    Inventors: Fabrizio Gasparini, Yves Auberson, Silvio Ofner, Terance W Hart, Kaspar Zimmerman
  • COMBINATION PRODUCTS
    Publication number: 20120122878
    Abstract: The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor.
    Type: Application
    Filed: June 30, 2008
    Publication date: May 17, 2012
    Inventors: Baltazar Gomez-Mancilla, Fabrizio Gasparini
  • ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY
    Publication number: 20120010263
    Abstract: The invention provides compounds of formula I wherein n, A, R, R?, R?, RO, X and Y are as defined in the description, and their preparation. The compounds of formula I are useful as pharmaceuticals.
    Type: Application
    Filed: September 22, 2011
    Publication date: January 12, 2012
    Inventors: Fabrizio Gasparini, Yves Auberson, Silvio Ofner, Terance William Hart, Kasper Zimmerman
  • ORGANIC COMPOUNDS
    Publication number: 20100249136
    Abstract: The invention concerns the use an mGluR modulator, e.g.
    Type: Application
    Filed: October 9, 2008
    Publication date: September 30, 2010
    Inventors: Daniel Umbricht, Baltazar Gomez-Mancilla, Fabrizio Gasparini, Therese Di Paolo